We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-3.45%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$334M
AUM Growth
-$21.5M
(-6.1%)
Cap. Flow
+$1.64M
Cap. Flow
% of AUM
0.49%
Top 10 Holdings %
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11
Top Buys
| 1 |
Cytokinetics
CYTK
|
+$3.77M |
| 2 |
Century Therapeutics
IPSC
|
+$3.65M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$2.89M |
| 4 |
ProQR Therapeutics
PRQR
|
+$2.88M |
| 5 |
Revolution Medicines
RVMD
|
+$2.41M |
Top Sells
| 1 |
Fate Therapeutics
FATE
|
+$5.56M |
| 2 |
ETNB
89bio
ETNB
|
+$4.13M |
| 3 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
+$3.65M |
| 4 |
Biohaven
BHVN
|
+$2.51M |
| 5 |
Viking Therapeutics
VKTX
|
+$2.09M |
Sector Composition
| 1 | Healthcare | 81.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $43.4M | 13.02% |
570,000
+4,000
| +0.7% | +$332K |
|
2
Stereotaxis
STXS
$161M
| $27.9M | 8.37% |
13,680,554
| – | – |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $14.9M | 4.47% |
612,975
+7,000
| +1% | +$153K |
|
4
Ascendis Pharma A/S
ASND
$17.4B
| $14.5M | 4.35% |
135,212
+5,000
| +4% | +$572K |
|
|
KRTX
5
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $14.3M | 4.28% |
78,573
+6,546
| +9% | +$1.25M |
|
6
iShares Biotechnology ETF
IBB
$9.2B
| $13.2M | 3.97% |
102,500
| – | – |
|
|
7
Revolution Medicines
RVMD
$39.2B
| $12.5M | 3.74% |
575,785
+98,000
| +21% | +$2.41M |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $11.8M | 3.52% |
261,235
| – | – |
|
9
Xenon Pharmaceuticals
XENE
$6.52B
| $11.3M | 3.39% |
316,092
| – | – |
|
|
10
Cytokinetics
CYTK
$11.2B
| $9.73M | 2.92% |
276,495
+92,500
| +50% | +$3.77M |
|
11
Syndax Pharmaceuticals
SNDX
$2.12B
| $9.44M | 2.83% |
447,073
| – | – |
|
12
DexCom
DXCM
$28.7B
| $7.85M | 2.35% |
67,552
| – | – |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $7.57M | 2.27% |
180,306
| – | – |
|
14
Neurocrine Biosciences
NBIX
$17.2B
| $7.55M | 2.26% |
74,615
+1,494
| +2% | +$155K |
|
|
MORF
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $6.76M | 2.03% |
179,467
-16,000
| -8% | -$590K |
|
16
IDEAYA Biosciences
IDYA
$3.54B
| $6.43M | 1.93% |
468,358
| – | – |
|
|
CSII
17
DELISTED
Cardiovascular Systems, Inc.
CSII
| $5.7M | 1.71% |
286,988
| – | – |
|
|
DICE
18
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $5.37M | 1.61% |
187,585
+64,085
| +52% | +$1.9M |
|
|
19
Viking Therapeutics
VKTX
$4.39B
| $5.31M | 1.59% |
319,155
-202,398
| -39% | -$2.09M |
|
|
MRUS
20
DELISTED
Merus
MRUS
| $5.23M | 1.57% |
283,998
+14,105
| +5% | +$246K |
|
21
AtriCure
ATRC
$1.76B
| $5.2M | 1.56% |
125,529
+53,500
| +74% | +$2.22M |
|
22
Nurix Therapeutics
NRIX
$2.44B
| $5.03M | 1.51% |
566,695
| – | – |
|
23
Edgewise Therapeutics
EWTX
$4.31B
| $4.89M | 1.47% |
733,239
-33,604
| -4% | -$311K |
|
|
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
| $4.84M | 1.45% |
616,032
| – | – |
|
|
25
BioCryst Pharmaceuticals
BCRX
$2.4B
| $4.6M | 1.38% |
551,500
+300,500
| +120% | +$2.89M |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML